ABUS vs EQIX · P/E 5.4, rev $6.2M vs P/E 79, rev $9.22B
Arbutus Biopharma Corp (ABUS) versus Equinix Inc (EQIX) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Equinix Inc (EQIX) is a reit - specialty company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported EQIX revenue for 2025-12-31 was $9.22B. Net income was $1.35B. Revenue was up 5.4% from 2024-12-31 to 2025-12-31. EQIX currently screens at market cap $74.23B and trailing P/E 79.4.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. EQIX currently screens at market cap $74.23B and trailing P/E 79.4.
Not investment advice. Open the ABUS and EQIX stock pages for the full models.
Not investment advice.